clinical trial · NCT07615166
Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice
Atherosclerotic Cardiovascular DiseaseAlirocumab 150 mgInclisiran
brief summary
The objective of this study is to evaluate LDL-C reduction over time among individuals initiating alirocumab 150 mg compared with inclisiran in routine clinical practice. The study will leverage observational data reflective of routine care and apply contemporary methods in target trial emulation and causal inference to estimate comparative treatment effects.
started
May 22, 2025
primary completion
Jun 30, 2026
completion
Jun 30, 2026
last updated
Sep 4, 2026
official title
Reduction in Low-Density Lipoprotein Cholesterol With Alirocumab 150 mg as Compared With Inclisiran: Comparative Evaluation Via Target-Trial Emulation and G-Computation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol